EASI (Eczema Area and Severity Index)
Eczema Area and Severity Index · Also known as: EASI Index
The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA).
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
EASI is the primary severity measure in clinical trials of atopic dermatitis across all therapeutic classes (topical, systemic, biologic). It is recommended by the US FDA and European Medicines Agency (EMA) as a co-primary or primary endpoint. In clinical practice, EASI is used in specialist dermatology settings to document baseline severity, track treatment response, and justify escalation to systemic therapy. It is less practical in primary care due to examination requirements and clinician training needs.
Strengths & limitations
- Highly responsive to treatment; sensitivity to change is superior to extent-only measures.
- Objective assessment reduces observer bias compared to global impression scores.
- Region-weighted algorithm reflects clinical priorities; head/neck and upper limb involvement weighted higher.
- Validated across pediatric (age 2+) and adult populations with strong inter-rater and test-retest reliability.
- Regulatory approval: accepted by FDA and EMA as primary efficacy endpoint in pivotal trials.
- Clear severity thresholds facilitate communication among clinicians and across studies.
- Requires trained clinician administration; not suitable for patient self-assessment or home monitoring.
- Time-consuming; typically 10–15 minutes, limiting practical use in high-volume clinics.
- Area estimation introduces variability; inter-rater agreement for percentage affected is moderate, especially for mid-range estimates (20–80%).
- Weighted regional factors may not apply uniformly across all populations (e.g., different clinical priorities in cosmetically sensitive regions across cultures).
- Sign intensity assessment (particularly lichenification and induration) can be subjective and training-dependent.
Frequently asked
Should EASI be combined with SCORAD, or is one sufficient?
EASI is purely objective (extent and clinical signs), while SCORAD includes subjective components (pruritus, sleep loss). In clinical trials, both may be used for complementary information: EASI tracks disease clearance, while SCORAD captures quality-of-life burden. In clinical practice, EASI alone is often sufficient for monitoring objective improvement. Use both if patient symptom burden is an outcome of interest.
What is the MCID (minimal clinically important difference) for EASI?
The MCID for EASI is 6.6 points. A reduction of ≥6.6 from baseline is considered clinically meaningful improvement. Additionally, EASI-50 (50% reduction) and EASI-75 (75% reduction) are standard response thresholds in trials; these are population-dependent but generally represent good and excellent responses, respectively.
Can EASI be administered remotely via video or photographs?
EASI requires in-person physical examination for reliable assessment of sign intensity (induration, excoriation, lichenification) and area estimation. Photograph or video-based assessment has not been formally validated and is subject to significant inter-rater error. Remote EASI is not recommended as a replacement for in-person assessment in clinical trials or specialist care.
How should EASI be used in pediatric patients?
EASI is validated from age 2 years onward. Examiners must adjust sign grading expectations slightly in infants and very young children, as lichenification may be less pronounced. Regional weightings remain the same across ages. In infants under 2 years, SCORAD or simplified measures may be more appropriate.
Sources
- Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18. DOI: 10.1034/j.1600-0625.2001.100102.x ↗
- Stalder JF, Taïeb A. Therapeutic classification of atopic dermatitis. Arch Dermatol. 2003;139(9):1221-1222. link ↗
How to cite this page
ScholarGate. (2026, June 3). Eczema Area and Severity Index. ScholarGate. https://scholargate.app/en/dermatology/easi
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →